A pen input mechanism is something I have never
seen in a corporate environment outside of me bringing one along to test.
Not exact matches
When a Millennial looks around and
sees his or her friends
in environments where their creativity and ingenuity are valued and implemented and growth is possible,
corporate stability and a competitive salary begin to lose their shine.»
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth
in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures
in European countries that may increase the amount of discount required on Gilead's products; an increase
in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift
in payer mix to more highly discounted payer segments and geographic regions and decreases
in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations
in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations
in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic
environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials
in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations
in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates
in the timelines currently anticipated; Gilead's ability to receive regulatory approvals
in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not
see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta
in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes
in its stock price,
corporate or other market conditions; fluctuations
in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time
in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
At least over the near term, we
see a reasonably constructive
corporate environment, and the consumer appears to be
in decent shape, too.
If you
saw this post, you know I recently accepted a new job
in a more
corporate environment.
There's an old saying «Dress for the job you want not the job you have» which is a really good quote to follow especially for any woman who wants to be taken seriously
in the
corporate world —
in an
environment where men are
seen in suits it makes sense to play the same game.
Once these products become more mainstream, we'll
see them
in use not only
in the classroom, but also
in corporate learning and training
environments.
We
see better prospects for equities
in an
environment of steady economic expansion, easy financial conditions and strong
corporate earnings.
-- Look back & you'll
see quite a few posts (over the last 12 - 18 mths) placing an ever - increasing emphasis on rotating into higher - quality / growth stocks (particularly, despite the recent Trump Bump, if we remain
in what seems like a never - ending low - growth low - return
environment — secular
corporate growth (& quality) should obviously be v highly valued
in such a paradigm).
«Since opening Fraser Suites Dubai
in 2010 we have
seen increased demand for small to medium sized events from discerning clients who seek a high quality
corporate meeting
environment that offers a full range of event and catering services.
It's much easier to embed values
in a
corporate environment than
in a partnership which many lawyers
see as nothing more than a cooperative venture where office expenses and staff are shared.»
What I often
see is that when people have worked
in a highly
corporate environment for most of their career or for their career so far, a little bit like I said before, they almost feel like all - or - nothing.
It's not hard to
see how the SPEAKE (a) R malware could be troublesome, especially
in a
corporate environment.
In a
corporate work
environment, it's frequent to
see a minimalistic interior so as portray a professional front.
In most
corporate companies, it is common to
see the workplace as a strict
environment following standard protocols.
This period lets the company get to know you on a more intimate level, gauge your skills and abilities
in action and
see if you are comfortable with the
corporate environment.
Agreed, And if they rented out access to that data base to like minded franchises and rented back from those like minded franchises their data at let's say $ 100,000 per year, that data being deemed
corporate intellectual property, we might create an
environment of professionalism never
seen before
in Canadian real estate.